Skip to main content
Erschienen in: Journal of Neurology 6/2016

02.04.2016 | Original Communication

Plasmapheresis and immunoadsorption in patients with steroid refractory multiple sclerosis relapses

verfasst von: Simon Faissner, Johanna Nikolayczik, Andrew Chan, Kerstin Hellwig, Ralf Gold, Min-Suk Yoon, Aiden Haghikia

Erschienen in: Journal of Neurology | Ausgabe 6/2016

Einloggen, um Zugang zu erhalten

Abstract

Patients suffering from multiple sclerosis (MS) are treated with high-dose intravenous steroids during acute relapses. In case of steroid refractory relapses, patients are treated with plasmapheresis or immunoadsorption. Until now data concerning the efficacy of both procedures are scarce. Visual evoked potentials (VEP), visual acuity and degree of remission of deficits caused by a relapse that had led to admission in MS patients (n = 48) treated with PLEX, IA or both in a single university centre setting were evaluated retrospectively. In a grouped analysis of patients treated with combined PLEX/IA, PLEX or IA alone, patients in all groups profited as assessed by VEP. Visual acuity also showed a trend towards a better performance, but lacked significance. In a subgroup analysis only concerning patients with initially pathological VEP there was a significant beneficial effect in the groups treated with PLEX/IA as well as in the group summarizing all patients. The combination of PLEX and IA provides a valid treatment option in steroid-refractory MS-relapses, and IA should be considered in acute relapses especially in patients with side effect of PLEX.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
2.
Zurück zum Zitat Szczepiorkowski ZM, Winters JL, Bandarenko N, Kim HC, Linenberger ML, Marques MB et al (2010) Guidelines on the use of therapeutic apheresis in clinical practice–evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis. J Clin Apher 25:83–177. doi:10.1002/jca.20240 CrossRefPubMed Szczepiorkowski ZM, Winters JL, Bandarenko N, Kim HC, Linenberger ML, Marques MB et al (2010) Guidelines on the use of therapeutic apheresis in clinical practice–evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis. J Clin Apher 25:83–177. doi:10.​1002/​jca.​20240 CrossRefPubMed
3.
Zurück zum Zitat Weinshenker BG, O’Brien PC, Petterson TM, Noseworthy JH, Lucchinetti CF, Dodick DW et al (1999) A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol 46:878–886CrossRefPubMed Weinshenker BG, O’Brien PC, Petterson TM, Noseworthy JH, Lucchinetti CF, Dodick DW et al (1999) A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol 46:878–886CrossRefPubMed
4.
Zurück zum Zitat Köhler W, Bucka C, Klingel R (2011) A randomized and controlled study comparing immunoadsorption and plasma exchange in myasthenic crisis. J Clin Apher 26(6):347–355CrossRefPubMed Köhler W, Bucka C, Klingel R (2011) A randomized and controlled study comparing immunoadsorption and plasma exchange in myasthenic crisis. J Clin Apher 26(6):347–355CrossRefPubMed
6.
Zurück zum Zitat Munemoto M, Otaki Y, Kasama S, Nanami M, Tokuyama M, Yahiro M et al (2011) Therapeutic efficacy of double filtration plasmapheresis in patients with anti-aquaporin-4 antibody-positive multiple sclerosis. J Clin Neurosci 18:478–480. doi:10.1016/j.jocn.2010.07.141 CrossRefPubMed Munemoto M, Otaki Y, Kasama S, Nanami M, Tokuyama M, Yahiro M et al (2011) Therapeutic efficacy of double filtration plasmapheresis in patients with anti-aquaporin-4 antibody-positive multiple sclerosis. J Clin Neurosci 18:478–480. doi:10.​1016/​j.​jocn.​2010.​07.​141 CrossRefPubMed
7.
Zurück zum Zitat Yoon MS, Chan A, Gold R (2011) Standard and escalating treatment of chronic inflammatory demyelinating polyradiculoneuropathy. Ther Adv Neurol Disord 4(3):193–200CrossRefPubMedPubMedCentral Yoon MS, Chan A, Gold R (2011) Standard and escalating treatment of chronic inflammatory demyelinating polyradiculoneuropathy. Ther Adv Neurol Disord 4(3):193–200CrossRefPubMedPubMedCentral
9.
11.
Zurück zum Zitat Wenning W, Haghikia A, Laubenberger J, Clifford DB, Behrens PF, Chan A et al (2009) Treatment of progressive multifocal leukoencephalopathy associated with natalizumab. N Engl J Med 361:1075–1080. doi:10.1056/NEJMoa0810257 CrossRefPubMed Wenning W, Haghikia A, Laubenberger J, Clifford DB, Behrens PF, Chan A et al (2009) Treatment of progressive multifocal leukoencephalopathy associated with natalizumab. N Engl J Med 361:1075–1080. doi:10.​1056/​NEJMoa0810257 CrossRefPubMed
12.
Zurück zum Zitat Heigl F, Hettich R, Arendt R, Durner J, Koehler J, Mauch E (2013) Immunoadsorption in steroid-refractory multiple sclerosis: clinical experience in 60 patients. Atheroscler Suppl 14(1):167–173CrossRefPubMed Heigl F, Hettich R, Arendt R, Durner J, Koehler J, Mauch E (2013) Immunoadsorption in steroid-refractory multiple sclerosis: clinical experience in 60 patients. Atheroscler Suppl 14(1):167–173CrossRefPubMed
14.
Zurück zum Zitat Goto H, Matsuo H, Nakane S, Izumoto H, Fukudome T, Kambara C et al (2001) Plasmapheresis affects T helper type-1/T helper type-2 balance of circulating peripheral lymphocytes. Ther Apher 5:494–496CrossRefPubMed Goto H, Matsuo H, Nakane S, Izumoto H, Fukudome T, Kambara C et al (2001) Plasmapheresis affects T helper type-1/T helper type-2 balance of circulating peripheral lymphocytes. Ther Apher 5:494–496CrossRefPubMed
Metadaten
Titel
Plasmapheresis and immunoadsorption in patients with steroid refractory multiple sclerosis relapses
verfasst von
Simon Faissner
Johanna Nikolayczik
Andrew Chan
Kerstin Hellwig
Ralf Gold
Min-Suk Yoon
Aiden Haghikia
Publikationsdatum
02.04.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Neurology / Ausgabe 6/2016
Print ISSN: 0340-5354
Elektronische ISSN: 1432-1459
DOI
https://doi.org/10.1007/s00415-016-8105-4

Weitere Artikel der Ausgabe 6/2016

Journal of Neurology 6/2016 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.